Research grant programme

What we do

Research grant programme

We fund New Zealand-based research projects to improve outcomes for breast cancer patients.

Breast Cancer Foundation NZ is New Zealand's largest non-government funder of breast cancer research. Our Research Grant Programme was established in September 2001, and over the years the work of some of NZ’s best clinicians and researchers has been boosted by our substantial grants.

Grant applications may be reviewed by the Foundation’s Medical Advisory Committee, or in partnership with other funders such as the Health Research Council, or by an independent review panel. The criteria for evaluating applications include an assessment of scientific merit, feasibility, originality, significance and ability to achieve the project’s objectives.

Applicants and institutions must be New Zealand based, although grants can be used to support participiation in international studies.

​Past Funding

CLOSED: Partnering for Innovation in Breast Cancer 2020: Our core research programme offered a single grant of $600,000 (paid over 4-5 years) to support an important study where a research team has defined a project and pathway with clear clinical potential. Applications were welcomed from researchers working in detection and diagnosis; development or trial of innovative and/or targeted treatments to improve early breast cancer survival; extending survival for metastatic breast cancer patients; improving clinical practice and supportive care for better patient outcomes.

CLOSED: Innovation and Technology in Breast Cancer 2018: Advances through harnessing technologies, not only in traditional cancer disciplines of radiology, pathology, surgery and oncology, but in wider fields such as bioengineering, immunology, genetics, chemistry, informatics, automation, mathematics and human interface technology.

CLOSED: Collaborate and Innovate in Breast Cancer 2017: Collaborative research with clear clinical potential (including clinical trials) in the following areas: early detection, new and improved targeted therapies, extending survival for metastatic breast cancer patients and improving clinical practice for better patient outcomes.